Multiple Companies

 
News Articles for Multiple Companies top ^
Biogen Idec (NASDAQ: BIIB) will present more than 90 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for multiple sclerosis (MS), as well as the company’s programs to address unmet needs in patient management, at the sixth Triennial Joint Meeting of ACTRIMS and ECTRIMS in Boston, September 10 – 13, 2014.
Sign-up for Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care investment picks
Today Biogen Idec (NASDAQ: BIIB) announced that five-year results from the ENDORSE Phase 3 extension study show TECFIDERA ® (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis (RRMS). These data will be presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS). Across all patients in the ENDORSE study who received TECFIDERA, including some patients who were treated for up to seven and a half years, the safety profile remained consistent with no new or worsening safety signals.
Sign-up for New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients investment picks
Today Biogen Idec (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY TM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe.
Sign-up for PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis investment picks
Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDY TM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). PLEGRIDY , the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe.
Sign-up for Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis investment picks
Today, INTERXION HOLDING NV (NYSE: INXN), a leading European provider of cloud and carrier-neutral colocation data centre services, launched its new service that enables private connections to multiple cloud service providers (CSPs). Cloud Connect will provide enterprises, service providers (SPs), system integrators (SIs) and carriers, private, secure and high performance connections to multiple clouds from within Interxion data centres, making it easier for them to shift business critical workloads and real time data to the cloud.
Sign-up for Interxion Launches Cloud Connect, Enabling Private Access to Multiple Clouds investment picks
2014/9/8
Genzyme , a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be featured during the 30 th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) being held in Boston Sept.
Sign-up for Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS investment picks
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). The randomized, double-blind study will evaluate the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy volunteers.
Sign-up for Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis investment picks
2014/7/31
-- Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition --
Sign-up for Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting investment picks
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study.
Sign-up for PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients investment picks
2014/6/20
By Eva Dou and Lorraine Luk Apple Inc. is planning multiple versions of its smartwatch, likely to be launched in the fall, people familiar with the matter said, as the company tries to counter wearable devices from rivals such as Google Inc. and Samsung Electronics Co.
Sign-up for Apple watch to feature multiple designs investment picks
First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study Trial Designed to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity Multiple Biomarkers to be Assessed DUBLIN, Ireland, July 31, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA) , a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that the first patient with Parkinson's disease has been successfully dosed in a Phase 1 multiple ascending dose clinical trial of PRX002, a potential disease-modifying treatment for Parkinson's disease.
Sign-up for Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease investment picks
2014/7/30
Article in "Neurosurgery" describes how RapidArc Radiosurgery treatments can be specially optimized to treat multiple brain metastases at the same time PALO ALTO, Calif.
Sign-up for Study Shows that RapidArc® Radiosurgery Substantially More Efficient and Comparable in Quality to Gamma Knife® in the Treatment of Multiple Brain Metastases investment picks
Results from a large-scale retrospective claims database study assessing real-world use of AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg will be presented by Acorda Therapeutics, Inc. (Nasdaq: ACOR ) and HealthCore Inc. at the 2014 Joint ACTRIMS-ECTRIMS Meeting.
Sign-up for Acorda Therapeutics and HealthCore to Present Real World Health Economics and Outcomes Data on Multiple Sclerosis Therapy AMPYRA investment picks
Anaconda Mining Intersects Multiple Zones Grading up to 3.17 g/t Gold Over 8.5 Meters in Down-Dip Drilling at Pine Cove Mine Canada NewsWire TORONTO , June 18, 2014 /CNW/ - Anaconda Mining Inc. ("Anaconda" or "the Company") – (TSX: ANX) is pleased to report additional diamond-drilling results from the down-dip area, Pine Cove mine, Baie Verte Peninsula , Newfoundland .
Sign-up for Anaconda Mining Intersects Multiple Zones Grading up to 3.17 g/t Gold Over 8.5 Meters in Down-Dip Drilling at Pine Cove Mine investment picks
Represents Second Subcontract Awarded to xG under this Multiple-Award Contract SARASOTA, Fla.
Sign-up for xG Technology Awarded Subcontract by CACI on $497 Million Multiple-Award Contract to Provide Communications and Networking Services to U.S. Army investment picks
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015 THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint investment picks
2014/8/14
SMART kapp wins Best New Product at InfoComm 2014 Audio-visual industry influencer rAVe also names SMART kapp as Best New Presentation Product SMART kapp named in multiple "Best of InfoComm" coverage CALGARY , Aug.
Sign-up for SMART kapp Earns Multiple Honors Following InfoComm Debut investment picks
Verint ® Systems Inc. (NASDAQ: VRNT) today announced that its Verint Mobile Workforce Optimization (WFO) solution is now available on multiple mobile platforms, including Google Android and Apple iOS.
Sign-up for Verint Workforce Optimization Solution Now Available on Multiple Mobile Platforms investment picks
Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)—an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant—have been published in the Sept.
Sign-up for Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Multiple Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Multinational Companies  |  Next: Multiple Managers